Physician profile
John Tumbush
NPI 1932200573
$2,700.07
in general payments reported to CMS, 2019-2025
36 companies · $65.40 in 2025
The $65.40 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $135 · 2021: $487 · 2022: $631 · 2023: $675 · 2024: $67.60 · 2025: $65.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773 · Education: $35.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $772.73 |
| Education | $35.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $630.15 | 2019-2025 | Ubrelvy, Vraylar |
| Pfizer INC. | $255.21 | 2019-2023 | |
| Novo Nordisk INC | $200.45 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $143.44 | 2019-2023 | Breztri |
| Lilly USA, LLC | $137.61 | 2019-2023 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $114.95 | 2019-2023 | Trelegy Ellipta, Bexsero, Shingrix |
| Merck Sharp & Dohme LLC | $114.26 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.27 | 2019-2023 | Trintellix |
| Sanofi-Aventis U.S. LLC | $95.22 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.01 | 2019-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.25 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $65.02 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $59.24 | 2019-2022 | |
| Exact Sciences Corporation | $58.03 | 2023 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $49.62 | 2023 | Auvelity |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $49.29 | 2022-2023 | |
| Allergan, INC. | $43.32 | 2019-2020 | |
| Abbott Laboratories | $41.65 | 2023 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $37.86 | 2019 | |
| Amarin Pharma, INC. | $37.32 | 2019-2020 | |
| Ptc Therapeutics, INC. | $35.07 | 2025 | Sephience |
| Amgen INC. | $29.66 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $24.77 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $22.53 | 2023 | Gvoke Hypopen |
| Sobi, INC | $21.65 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.77 | 2023 | |
| Lundbeck LLC | $17.83 | 2023 | Rexulti |
| Shire North American Group INC | $17.71 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.97 | 2021 | |
| Bausch Health US, LLC | $14.54 | 2022 | |
| Philips North America LLC | $14.38 | 2024 | (Ck7) Extended Holter |
| Otsuka America Pharmaceutical, INC. | $14.28 | 2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $14.24 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.21 | 2022 | |
| Amneal Pharmaceuticals LLC | $11.24 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tumbush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.